XENE - Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) | Benzinga
VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).
Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "Xenon will have another strong presence at AES this year, with many presentations and activities aimed at raising awareness about our XEN1101 program with the epileptologists and neurologists in attendance. Importantly, we are looking forward to presenting new interim data from our ongoing open-label extension study from our Phase 2b X-TOLE trial. These new data demonstrate impressive seizure freedom rates, including almost one in four patients who were on treatment for at least two years achieving at least 12 months of consecutive seizure freedom. In addition, we have now generated more than 500 patient years of safety data through our open label study, continuing to build on the significant body of evidence to support XEN1101's safety and tolerability profile."
Mr. Mortimer continued, "In addition, at our Xenon-sponsored scientific exhibit, we will present survey results on general burden of illness, quality of life, and mental health burden of illness from patients reporting focal onset seizures, which suggest that depression and anxiety, common comorbidities in epilepsy, further exacerbate the burden of epilepsy and may require additional care or support. Also at our scientific exhibit, we will feature a summary of the promising topline data from our XEN1101 Phase 2 X-NOVA study in major depressive disorder, or MDD, that we released earlier this week, and we look forward to engaging with the neurology community on these important data."
AES XEN1101 Poster Highlights
Poster No. 1.277 (French et al.) "Interim Long-Term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update From an Ongoing, Open-Label Extension of a Phase 2b Study (X-TOLE) in Adults With Focal Epilepsy"
- Once daily (QD) dosing of 20 mg of XEN1101 with food yielded long-term efficacy in this interim analysis with 60% retention at 24 months.
- During open-label extension (OLE) study months 18 to 30, there was a sustained monthly reduction in seizure frequency (78%–95% median percent change) from double-blind period baseline, and higher reductions were observed for patients who were receiving one to two anti-seizure medications (ASMs) at baseline compared to those receiving three ASMs.
- Seizure freedom for ?3-month, ?6-month, and ?12-month consecutive durations was achieved in 37.5%, 22.2%, and 14.9% of all patients enrolled in the OLE (n=275), respectively.
- Seizure freedom for ?3-month, ?6-month, and ?12-month consecutive durations was achieved in 56.4%, 34.5% and 23.6% of those patients with at least 24 months of treatment in the OLE (n=165), respectively.
- XEN1101 continues to be generally well-tolerated in the OLE with adverse events (AEs) consistent with prior results ...